N,N-diethyl-4-(hydroxymethyl)benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N-diethyl-4-(hydroxymethyl)benzamide
• 英文别名: 4-diethylcarbamoylbenzyl alcohol
• 化学式: C₁₂H₁₇NO₂
• mdl: MFCD20042840
• 分子量: 207.272
• InChiKey: FTLBIKGUTGBHFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N-diethyl-4-(hydroxymethyl)benzamide 在 copper(II) perchlorate hexahydrate 、 叠氮基三甲基硅烷 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 20.0h， 以73%的产率得到4-cyano-N,N-diethylbenzamide
  参考文献：
  名称：

  A novel oxidative transformation of alcohols to nitriles: an efficient utility of azides as a nitrogen source

  摘要：

  已开发出一种高效的方法论，能够将苄醇和肉桂醇氧化为其相应的腈类化合物，并获得极佳的产率。该方法论采用DDQ作为氧化剂，TMSN3作为氮源，在微量Cu(ClO4)2·6H2O催化剂存在下进行反应。

  DOI：

  10.1039/c2cc31256e
• 作为产物：
  描述：

  N,N-二乙基苯甲酰胺-4-羧醛 在 sodium tetrahydroborate 作用下， 生成 N,N-diethyl-4-(hydroxymethyl)benzamide
  参考文献：
  名称：

  A novel oxidative transformation of alcohols to nitriles: an efficient utility of azides as a nitrogen source

  摘要：

  已开发出一种高效的方法论，能够将苄醇和肉桂醇氧化为其相应的腈类化合物，并获得极佳的产率。该方法论采用DDQ作为氧化剂，TMSN3作为氮源，在微量Cu(ClO4)2·6H2O催化剂存在下进行反应。

  DOI：

  10.1039/c2cc31256e

文献信息

• A simple solid phase diversity linker strategy using enol phosphonates
  作者：Ian B. Campbell、Jun Guo、Edward Jones、Patrick. G. Steel

  DOI：10.1039/b411111g

  日期：——

  Polymer bound lactam enol phosphonates can be easily generated using simple phenol on polystyrene resin. These stable, storable compounds can be released in a diversity cleavage strategy, using Suzuki cross coupling conditions, to provide 2-arylenamides in moderate to good overall yields.

  聚合物结合的内酰胺烯醇膦酸酯可以在聚苯乙烯树脂上使用简单的苯酚轻松生成。这些稳定的，可储存的化合物可以使用铃木交叉偶联条件以多样性裂解策略释放，从而以中等至良好的总收率提供2-芳酰胺。
• A General, Practical Triethylborane-Catalyzed Reduction of Carbonyl Functions to Alcohols
  作者：Dongjie Peng、Mintao Zhang、Zheng Huang

  DOI：10.1002/chem.201502942

  日期：2015.10.12

  A combination of the abundant and low‐cost triethylborane and sodium alkoxide generates a highly efficient catalyst for reduction of esters, as well as ketones and aldehydes, to alcohols using an inexpensive hydrosilane under mild conditions. The catalyst system exhibits excellent chemoselectivity and a high level of functional group tolerance. Mechanistic studies revealed a resting state of sodium

  大量廉价的三乙基硼烷与烷醇钠的组合可生成一种高效催化剂，用于在温和条件下使用廉价的氢化硅烷将酯以及酮和醛还原为醇。该催化剂体系表现出优异的化学选择性和高水平的官能团耐受性。机理研究表明，三乙基烷氧基棉酸钠的静置状态是BEt 3与醇钠反应的产物。该硼酸盐物质与氢硅烷反应形成NaBEt 3 H，这会迅速还原酯。
• Schwartz Reagents: Methods of In Situ Generation and Use
  申请人：Zhao Yigang

  公开号：US20100145060A1

  公开（公告）日：2010-06-10

  Embodiments of the invention provide a method of using Schwartz Reagent, Cp 2 Zr(H)Cl, without accumulating or isolating it. Methods provide mixtures of Cp 2 ZrCl 2 , reductants that selectively reduce Cp 2 ZrCl 2 , and substrates. After reaction of Cp 2 ZrCl 2 and the reductant, an intermediate reduction product is formed, apparently Schwartz Reagent. The in situ Schwartz Reagent then selectively reduces certain functional groups on the substrate. Substrates include tertiary amides, tertiary benzamides, aryl O-carbamates, and heteroaryl N-carbamates, which are reduced to aldehydes, benzaldehydes, aromatic alcohols, and heteroaromatics, respectively. Compared to prior methods, reagents are inexpensive and stable, reaction times are short, and reaction temperature in certain cases is conveniently room temperature. It has been estimated that using the in situ method described herein instead of synthesized or commercially obtained Schwartz Reagent provides a 50% reduction in cost.

  本发明的实施例提供了一种使用Schwartz试剂，Cp2Zr（H）Cl的方法，而无需积累或隔离它。方法提供了Cp2ZrCl2的混合物，选择性还原Cp2ZrCl2的还原剂，以及底物。在Cp2ZrCl2和还原剂发生反应后，形成了一个中间还原产物，显然是Schwartz试剂。然后，原位的Schwartz试剂选择性地还原底物上的某些官能团。底物包括三级酰胺、三级苯酰胺、芳基O-氨基甲酸酯和杂环N-氨基甲酸酯，它们分别被还原为醛、苯甲醛、芳香醇和杂环化合物。与先前的方法相比，试剂价格低廉且稳定，反应时间短，某些情况下的反应温度方便地为室温。据估计，使用本文描述的原位方法而不是合成或商业获得的Schwartz试剂可使成本降低50%。
• Phenoxyalkylamine derivatives useful as opioid receptor agonists
  申请人：——

  公开号：US20030171370A1

  公开（公告）日：2003-09-11

  A medicament useful for preventive and/or therapeutic treatment of nerve system diseases which comprises, as an active ingredient, a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof: 1 wherein, X represents a group represented by the following general formula (II), (III), (IV), (V), or (VI), 2 “A” represents a saturated or unsaturated 3- to 6-membered carbocyclic group and the like, “B” represents CH 2 and the like, “n” represents 0 to 2, R 1 represents a hydrogen atom, a halogen atom and the like, R 2 , R 3 , and R 7 to R 14 represent a hydrogen atom, a lower alkyl group which may be substituted and the like, R 4 represents a hydrogen atom, a lower alkyl group which may be substituted and the like, R 5 represents a hydrogen atom, a halogen atom and the like, R 6 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, and R 5 and R 6 , R 7 and R 8 , R 9 and R 10 , or R 11 and R 12 may bind to each other to form a cyclic structure.

  一种用于预防和/或治疗神经系统疾病的药物，其活性成分为以下通用式（I）或其药理学可接受的盐所代表的化合物： 其中，X代表以下通用式（II）、（III）、（IV）、（V）或（VI）所代表的基团，“A”代表饱和或不饱和的3-至6-成员碳环基团等，“B”代表CH2等，“n”代表0至2，R1代表氢原子、卤素原子等，R2、R3和R7至R14代表氢原子、可能被取代的较低烷基基团等，R4代表氢原子、可能被取代的较低烷基基团等，R5代表氢原子、卤素原子等，R6代表饱和或不饱和的单环或双环碳环基团等，且R5和R6、R7和R8、R9和R10，或R11和R12可以结合在一起形成环状结构。
• Phenoxyalkylamine derivatives useful as opioid delta receptor ligands
  申请人：Tsushima Masaki

  公开号：US20050148583A1

  公开（公告）日：2005-07-07

  A medicament useful for preventive and/or therapeutic treatment of nerve system diseases which comprises, as an active ingredient, a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof: wherein, X represents a group represented by the following general formula (II), (III), (IV), (V), or (VI), “A” represents a saturated or unsaturated 3- to 6-membered carbocyclic group and the like, “B” represents CH 2 and the like, “n” represents 0 to 2, R 1 represents a hydrogen atom, a halogen atom and the like, R 2 , R 3 , and R 7 to R 14 represent a hydrogen atom, a lower alkyl group which may be substituted and the like, R 4 represents a hydrogen atom, a lower alkyl group which may be substituted and the like, R 5 represents a hydrogen atom, a halogen atom and the like, R 6 represents a saturated or unsaturated monocyclic or bicyclic carbocyclic group and the like, and R 5 and R 6 , R 7 and R 8 , R 9 and R 10 , or R 11 and R 12 may bind to each other to form a cyclic structure.

  一种用于神经系统疾病的预防和/或治疗的药物，其包括以下通式（I）所表示的化合物或其药学上可接受的盐作为活性成分： 其中，X代表以下通式（II），（III），（IV），（V）或（VI）所表示的基团，“A”代表饱和或不饱和的3-至6-成员的碳环基团等，“B”代表CH2等，“n”代表0至2，“R1”代表氢原子，卤原子等，“R2”，“R3”和“R7”至“R14”代表氢原子，可被取代的较低烷基基团等，“R4”代表氢原子，可被取代的较低烷基基团等，“R5”代表氢原子，卤原子等，“R6”代表饱和或不饱和的单环或双环碳环基团等，“R5”和“R6”，“R7”和“R8”，“R9”和“R10”，或“R11”和“R12”可以结合在一起形成环状结构。